Integrative Approaches to Managing Myeloproliferative Neoplasms: the Role of Nutrition, Exercise, and Psychological Interventions
- 90 Downloads
Purpose of Review
Myeloproliferative neoplasms (MPNs) have a high symptom burden that affects functional status, emotional well-being, and quality of life for patients. Symptom control continues to be a challenging therapeutic goal despite available pharmacologic interventions. The goal of this review is to detail recent efforts that have focused on non-pharmacologic interventions, such as wholistic or integrative medicine, as an adjunctive method to alter symptom burden in this population.
We discuss the ongoing physical, nutritional, and psychological interventional efforts which represent promising non-traditional interventions to date to help reduce symptom in MPN patients. In this article, we highlight the early promising data and importance of these various non-pharmacological interventions to dampen symptom burden and reduce disease-related inflammation.
Nonpharmacologic interventions represent promising therapeutic strategies to alter traditional MPN treatment paradigms and improve MPN patient care.
KeywordsMyeloproliferative neoplasms Hematopoietic stem cells Chronic inflammation Symptom burden Quality of life Non-pharmacologic interventions Integrative medicine
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.O'Sullivan J and Mead AJ. Heterogeneity in myeloproliferative neoplasms: causes and consequences. Adv Biol Regul. 2018. https://doi.org/10.1016/j.jbior.2018.11.007.
- 2.••Scherber RM, Kosiorek HE, Senyak Z, Dueck AC, Clark MM, Boxer MA, et al. Comprehensively understanding fatigue in patients with myeloproliferative neoplasms. Cancer. 2016;122(3):477–85 Details the multifactorial nature of symptom burden in MPN populations and details the early findings of patient-directed integrative treatments to impact symptom burden and fatigue.CrossRefGoogle Scholar
- 4.Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30(33):4098–103.CrossRefGoogle Scholar
- 8.Geyer H, et al. Symptom burden profile in myelofibrosis patients with thrombocytopenia: lessons and unmet needs. 2015;126(23):4080–4080.Google Scholar
- 10.Geyer, HL and R.A. Mesa, Therapy for myeloproliferative neoplasms: when, which agent, and how?. 2014;124:(24): p. 3529–3537.Google Scholar
- 11.Huberty J, et al. Online-streamed yoga as a non-pharmacologic symptom management approach in myeloproliferative neoplasms. 2016;128(22):5478–5478.Google Scholar
- 12.Geyer H, et al. Symptomatic profiles of patients with polycythemia vera: implication of inadequately controlled disease. 2016;34(2):151–159. https://doi.org/10.1200/jco.201562.9337.
- 13.Geyer H, et al. Symptomatic profiles of patients with polycythemia vera: implications of inadequately controlled disease. 2016;34(2):151–159.Google Scholar
- 14.Craver BM, et al. The critical role of inflammation in the pathogenesis and progression of myeloid malignancies. Cancers (Basel) 2018;10(4). https://doi.org/10.3390/cancer10040104.
- 15.Scherber R, et al. The relationship of BMI to symptom burden in the myeloproliferative neoplasms. Haematologia. 2017;102(S2):215667.Google Scholar
- 18.••Brochmann N, Flachs EM, Christensen AI, Bak M, Andersen CL, Juel K, et al. Anxiety and depression in patients with Philadelphia-negative myeloproliferative neoplasms: a nationwide population-based survey in Denmark. Clin Epidemiol. 2019;11:23–33 Demonstrates the importance of cognitive and emotional issues in MPN patients.CrossRefGoogle Scholar
- 19.Eckert R, et al. A pilot study of online yoga to improve fatigue and quality of life in myeloproliferative neoplasm patients. 2017;130(Suppl 1):3443–3.Google Scholar
- 22.Vowles KE, et al. An analysis of within-treatment change trajectories in valued activity in relation to treatment outcomes following interdisciplinary acceptance and commitment therapy for adults with chronic pain. Behav Res Ther. 2019;115:46–54. https://doi.org/10.1016/j.brat.2018.10.012.
- 24.Mosher CE, Secinti E, Li R, Hirsh AT, Bricker J, Miller KD, et al. Acceptance and commitment therapy for symptom interference in metastatic breast cancer patients: a pilot randomized trial. Support Care Cancer. 2018;26(6):1993–2004. https://doi.org/10.1007/s00520-018-4045-0.
- 25.Padrnos L, Kosiorek H, Scherber R, Knight E, Cuc A, Stonnington C, Dueck A, Geda Y, Mesa R. Myeloproliferative neoplasms and acceptance and commitment therapy: an ongoing feasibility study aimed at symptom mitigation and quality of life. EHA, 2018;(216851).Google Scholar
- 27.Mesa RA, et al. Weight loss, splenomegaly, and hypocholesterolemia in myeloproliferative neoplasms: patterns and relevance from the Pre JAK2 inhibitor era 2009;114(22):3918–3918.Google Scholar
- 29.Chrysohoou C, Panagiotakos DB, Pitsavos C, Das UN, Stefanadis C. Adherence to the Mediterranean diet attenuates inflammation and coagulation process in healthy adults: the ATTICA Study. J Am Coll Cardiol. 2004;44(1):152–158. https://doi.org/10.1016/j.jacc.2004.03.039.
- 32.Scherber R, et al. Nutritional needs and preferences of myeloproliferative neoplasm patients: Phase I A of the NUTRIENT Study. EHA Abstract pending acceptance, 2017.Google Scholar
- 33.Scherber R, et al. Needs and preferences regarding nutrition and supplement use among individuals with myeloproliferative neoplasms. Proceedings of the 9th international congress on myeloproliferative neoplasms. 2017.Google Scholar